Research programme: amino acids therapeutics - Axcella

Drug Profile

Research programme: amino acids therapeutics - Axcella

Alternative Names: DAACS™; Defined Amino Acid Compositions

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Axcella Health
  • Class Amino acids peptides and proteins
  • Mechanism of Action Amino acid replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy; Muscular atrophy; Myotonic dystrophy; Non-alcoholic fatty liver disease

Most Recent Events

  • 14 Sep 2017 Axcella Health plans multiple proof-of-concept trials in last quarter of 2017
  • 04 Jan 2017 Preclinical trials in Epilepsy in USA (unspecified route)
  • 04 Jan 2017 Preclinical trials in Muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top